以嶺藥業(002603.SZ)直線拉昇封漲停板 創歷史新高 連花清瘟增加"新冠"功能主治
格隆匯4月14日丨以嶺藥業(002603.SZ)午後直線拉昇封漲停板,報31.32元,創歷史新高價,漲停封單超17萬手,暫成交34.11億元,最新總市值377億元。該股年內已累漲逾150%。以嶺藥業午間發佈公告稱,近日公司和全資子公司北京以嶺藥業有限公司收到國家藥品監督管理局下發的連花清瘟膠囊和連花清瘟顆粒的關於新增適應症申請的《藥品補充申請批件》。兩個批件為連花清瘟膠囊和連花清瘟顆粒在原批准適應症的基礎上,增加“新型冠狀病毒肺炎輕型、普通型”新適應症的批覆。同時,連花清瘟膠囊此次新批處方藥説明書,批件中未否定原非處方藥的定位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.